Pharming Group (NASDAQ:PHAR - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $11.24, but opened at $12.61. Pharming Group shares last traded at $12.41, with a volume of 3,552 shares.
Analyst Ratings Changes
A number of research firms recently commented on PHAR. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer raised their price target on shares of Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th.
Check Out Our Latest Stock Analysis on Pharming Group
Pharming Group Trading Down 7.8%
The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The stock has a market capitalization of $762.63 million, a P/E ratio of -43.12 and a beta of 0.02. The firm's fifty day simple moving average is $9.14 and its 200 day simple moving average is $8.96.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. As a group, equities research analysts forecast that Pharming Group will post -0.2 EPS for the current fiscal year.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
